Firstly, there is a lack of some important information related to molecular pathology data in patients from 2010 to 2016, which may have influenced the survival time of GBM, such as MGMT, TP53, etc. Then, lies in the fact that it is a single-centre retrospective study with a small sample size, and due to the limitations of retrospective study methodology, there may be selection bias and information bias, and any pathology-related information that has not been collected may affect the results of the study. The gene discussed is TP53; the disease is glioblastoma.